Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AromaLeap is a digital olfaction company that utilizes artificial intelligence and advanced sensor technology to digitize and analyze scents for healthcare and industrial applications. The company develops electronic nose systems capable of detecting specific volatile organic compounds (VOCs) in human breath and skin odors, which serve as biomarkers for various diseases. These biosensors are integrated with machine learning algorithms to provide non-invasive, rapid screening for conditions such as lung cancer and gastric cancer. AromaLeap's platform aims to transform medical diagnostics by offering a low-cost, accurate alternative to traditional imaging and laboratory tests. Beyond healthcare, the company provides scent-recognition solutions for the automotive, environmental, and consumer electronics sectors.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Aromaleap.